May 2026 Psychedelic Bill Roundup

With most legislatures now adjourned, the 2026 psychedelic policy reform push has passed its peak. Of the 115 psychedelics-related bills we have tracked this year (108 state and 7 federal), 17 distinct measures have been signed into law; more than a quarter of those signings were in May alone. On the other side, 2 bills fell to Governor vetoes, 44 bills died with their sessions, and around 50 measures remain pending, at least on paper, largely in legislatures yet to adjourn.

While psilocybin-focused measures lead the enactment count, anchored predominantly by trigger rescheduling laws of the pharmaceutical variety, ibogaine is arguably the year’s defining theme. Of the 25 ibogaine-focused bills introduced across 14 states in 2026, 6 have now been enacted, with New Hampshire’s HB1772 one vote from passage. If that is successful, it would push the success rate of ibogaine bills over 25% this year, which is well above the broader pack of psychedelics bills.

The state-by-state roundup below recaps May’s most significant developments, as well as some developments from June thus far.